Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 15, 2020 08:30 ET | Source: KemPharm

Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today CELEBRATION, Fla., Jan. 15, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical...
December 18, 2019 07:15 ET | Source: KemPharm

KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date KemPharm Will Host a Conference Call...
November 14, 2019 16:55 ET | Source: KemPharm

KemPharm Reports Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET CELEBRATION, Fla., Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:...
November 12, 2019 08:30 ET | Source: KemPharm

KemPharm to Report Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled forThursday, November 14, 2019, 5:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc....
October 31, 2019 08:30 ET | Source: KemPharm

KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access CELEBRATION, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company...
October 22, 2019 16:15 ET | Source: KemPharm

KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a...
September 20, 2019 17:00 ET | Source: KemPharm

KemPharm Provides Updates Regarding its Board of Directors

CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...
September 17, 2019 08:30 ET | Source: KemPharm

KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...
September 05, 2019 07:30 ET | Source: KemPharm

KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
September 04, 2019 08:00 ET | Source: KemPharm

KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide...